Real World Patient Perceptions of the use of Tazarotene 0.1% Foam in the Treatment of Acne Vulgaris

Main Article Content

James Q Del Rosso
Corey L Hartman
Caitlin Lewis
Rhonda Schreiber

Keywords

Acne Vulgaris, Acne, Tazarotene, retinoid

Abstract

Abstract not available.

References

1. Dréno B, Thiboutot D, Gollnick H, Finlay AY, Layton A, Leyden JJ, Leutenegger E, Perez M Global Alliance to Improve Outcomes in Acne Large scale worldwide observational study of adherence with acne therapy Int J Dermatol 2010 Apr 49 4 448 56

2. Kircik LH Importance of vehicles in acne therapy J Drugs Dermatol 2011 Jun 10 6 s 17 23

3. Del Rosso JQ, Kircik LH, Zeichner J, Stein Gold L The Clinical Relevance and Therapeutic Benefit of Established Active Ingredients Incorporated into Advanced Foam Vehicles Vehicle Characteristics Can Influence and Improve Patient Outcomes J Drugs Dermatol 2019 Feb 1 18 2 s) s 100 s 107

4. Eastman WJ, Malahias S, Delconte J, DiBenedetti D Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis Cutis 2014 Jul 94 1 46 53

5. Smith JA, Narahari S 2 Hill D, Feldman SR Tazarotene foam, 0 1 for the treatment of acne Expert Opin Drug Saf 2016 Jan 15 1 99 103

6. Feldman SR, Werner CP, Alió Saenz AB The efficacy and tolerability of tazarotene foam, 0 1 in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle controlled, double blind studies J Drugs Dermatol 2013 Apr 12 4 438 46

7. Epstein EL, Stein Gold L Safety and efficacy of tazarotene foam for the treatment of acne vulgaris Clin Cosmet Investig Dermatol 2013 May 14 6 123 5

8. Data on file, Mayne Pharma